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Objectives This study sought to compared the use and effectiveness of bleeding avoidance strategies (BAS) by sex.
Background Women have higher rates of bleeding following percutaneous coronary intervention (PCI).
Methods Among 570,777 men (67.5%) and women (32.5%) who underwent PCI in the National Cardiovascular Data Reg-
istry’s CathPCI Registry between July 1, 2009 and March 31, 2011, in-hospital bleeding rates and the use of
BAS (vascular closure devices, bivalirudin, radial approach, and their combinations) were assessed. The relative
risk of bleeding for each BAS compared with no BAS was determined in women and men using multivariable
logistic regressions adjusted for clinical characteristics and the propensity for receiving BAS. Finally, the absolute
risk differences in bleeding associated with BAS were compared.
Results Overall, the use of any BAS differed slightly between women and men (75.4% vs. 75.7%, p  0.01). When BAS
was not used, women had significantly higher rates of bleeding than men (12.5% vs. 6.2%, p  0.01). Both
sexes had similar adjusted risk reductions of bleeding when any BAS was used (women, odds ratio: 0.60, 95%
confidence interval [CI]: 0.57 to 0.63; men, odds ratio: 0.62, 95% CI: 0.59 to 0.65). Women and men had lower
absolute bleeding risks with BAS; however, these absolute risk differences were greater in women (6.3% vs.
3.2%, p  0.01).
Conclusions Women continue to have almost twice the rate of bleeding following PCI. The use of any BAS was associated
with a similarly lower risk of bleeding for men and women; however, the absolute risk differences were sub-
stantially higher in women. These data underscore the importance of applying effective strategies to limit
post-PCI bleeding, especially in women. (J Am Coll Cardiol 2013;61:2070–8) © 2013 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.030Peri-procedural bleeding is the most common noncardiac
complication following percutaneous coronary intervention
(PCI) and is associated with high morbidity and mortality
(1–3). Historically, women have been at higher risk for
peri-procedural bleeding following PCI compared with men
(4–10). Bleeding avoidance strategies (BAS), including
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May 21, 2013:2070–8 Sex and Bleeding Avoidance Strategieswomen, who are known to be at high risk for bleeding, receive
BAS during PCI as frequently as men in contemporary
practice has not been determined. Furthermore, whether
BAS are associated with similar reductions in peri-
procedural bleeding in women compared with men is not
known.
To address these gaps in knowledge, we compared the use
of BAS (VCDs, bivalirudin, radial access, or their combi-
nations) by sex and conducted an observational comparative
effectiveness study of BAS to determine whether the lower
risk of bleeding associated with BAS use was similar
between women and men. This study was designed to
provide a contemporary assessment of the use of BAS and
the extent to which BAS may reduce the risk of this
common adverse consequence in women undergoing PCI.
Methods
Data source. Data were obtained from the National Cardio-
vascular Data Registry’s (NCDR) CathPCI Registry, which is
an initiative of the American College of Cardiology (ACC)
Foundation and the Society for Cardiovascular Angiography
and Interventions. A detailed description of the registry has
been published previously (14). Demographic, clinical, proce-
dural, and institutional data elements for PCI procedures are
collected at more than 1,400 participating centers throughout
the United States (80% of hospitals with invasive catheter-
zation laboratories). Data are entered via a secure Web-based
latform or via software provided by ACC certified vendors.
ata quality assurance measures include automatic system
alidation and reporting of data completeness, random on-site
uditing of participating centers, and education and training of
ite data managers (15).
tudy population. All patients within the CathPCI Reg-
stry discharged after PCI between July 1, 2009 and March
1, 2011 were candidates for inclusion (n  606,382
patients at 1,232 sites). Patients whose PCI did not use
either a radial or femoral approach (n  1,997) and those
who underwent more than 1 PCI procedure during their
hospital stay (n 12,488) were excluded. Patients were also
excluded if they had cardiogenic shock (n  12,746), died
the same day as the procedure (n  568), or if they were
missing data to determine a bleeding event (n  165).
Patients were also excluded if they received manual com-
pression and a closure device (n  7,382) because it was felt
these cases might reflect failed deployment of the closure
device. In addition, patients who had radial access and
received a closure device (n  106) or bivalirudin, radial
access, and a closure device (n 153) were excluded because
this combination of treatments was felt to reflect procedures
with combined femoral and radial access that might inher-
ently pose a higher risk for peri-procedural bleeding irre-
spective of the BAS strategy used. After applying exclusions
(total of 5.9% excluded), 570,777 patients at 1,230 sites
remained. Among the final study cohort, 385,103 (67.5%)
were men and 185,674 (32.5%) were women (Fig. 1).Study outcomes. In-hospital
bleeding complications following
PCI were ascertained and re-
ported by participating centers.
Peri-procedural bleeding was de-
fined according to the CathPCI
V4 data definitions and included:
1) any documented bleeding
event that occurred within 72 h
after PCI regardless of site (in-
cluding access site bleeding, ac-
cess site hematoma, retroperito-
neal bleeding, gastrointestinal
bleeding, genital-urinary bleed-
ing, intracerebral hemorrhage);
2) pericardial tamponade; 3) any
transfusion following PCI (ex-
cept among patients with pre-
procedure hemoglobin 8 g/dl
or those who underwent coro-
nary artery bypass grafting dur-
ing their hospital stay); or 4) any
absolute decline of 3 g/dl in
hemoglobin level (except for patients with pre-procedure
hemoglobin 16 g/dl) (16).
Bleeding avoidance strategies. BAS studied included:
1) VCDs alone (see Online Table 1 for list of specific
devices included); 2) bivalirudin alone (Angiomax, The
Medicines Company, Parsippany, New Jersey); 3) bivaliru-
din with VCD; 4) radial access alone; and 5) radial access
with bivalirudin. Patients receiving manual compression
who did not receive VCD, bivalirudin, or radial access
served as the referent group for effectiveness comparisons.
Pre-procedural bleeding risk estimation. Estimated
bleeding risk scores based upon pre-procedural patient
characteristics were derived using the CathPCI bleeding
risk model, version 4 (17). Risk scores were generated for
each patient based on the inverse logarithmic sum of the
beta coefficients for each of the following pre-PCI variables:
sex, age, body mass index, previous cerebrovascular disease,
chronic lung disease, previous PCI, peripheral vascular
disease, diabetes mellitus, left ventricular ejection fraction,
chronic kidney disease, PCI status (defined as elective,
urgent, emergent, or salvage), ST-segment elevation myo-
cardial infarction (STEMI), non–ST-segment elevation
myocardial infarction (NSTEMI), cardiac arrest within
24 h, pre-procedure New York Heart Association (NYHA)
class IV heart failure, estimated glomerular filtration rate,
pre-procedure hemoglobin, pre-procedure Thrombolysis In
Myocardial Infarction flow, number of diseased vessels, use
of fibrinolytics before PCI, subacute stent thrombosis,
Society for Cardiovascular Angiography and Intervention
lesion class, and lesion location (proximal left anterior
descending or left main vs. other).
Statistical analysis. Baseline demographic, clinical, proce-
Abbreviations
and Acronyms
ACC  American College of
Cardiology
BAS  bleeding avoidance
strategy
CI  confidence interval
NCDR  National
Cardiovascular Data
Registry
NSTEMI  non–ST-
elevation myocardial
infarction
NYHA  New York Heart
Association
OR  odds ratio
PCI  percutaneous
coronary intervention
STEMI  ST-elevation
myocardial infarction
VCD  vascular closure
devicedural, and hospital characteristics were compared between
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Sex and Bleeding Avoidance Strategies May 21, 2013:2070–8women and men using Pearson chi-square tests for categor-
ical variables and Kruskal-Wallis tests for continuous vari-
ables. In the primary outcomes analysis, rates of in-hospital
bleeding were compared between women and men. Next,
the use of each BAS was compared by sex. Given the
previous studies that demonstrated a risk treatment paradox
for BAS use (i.e., lower rates of use among those at highest
predicted risk for bleeding), rates of use of any BAS were
compared between women and men among tertiles of
bleeding risk (defined as low [2.3%], intermediate [2.3%
to 5.0%], and high [5%]) according to the CathPCI
bleeding risk model, version 4 (11). Because female sex was
a determinant of higher bleeding risk, there were a larger
proportion of women in the higher tertiles of bleeding risk.
To compare the effectiveness of BAS strategies by sex, the
crude relative risk ratios in bleeding for any BAS and
individual BAS types versus no BAS were compared be-
tween women and men. Next, among strata of women and
men, multivariable logistic regression was used to assess the
relationship between each BAS strategy (compared with none)
and peri-procedural bleeding, adjusting for baseline patient,
procedural, and site characteristics (all Tables 1 and 2 variables,
xcept estimated bleeding risk), as well as clustering by site
nd the propensity to receive each BAS.
Propensity scores for each BAS were calculated in women
nd men to minimize the effect of potential selection bias for
AS choice. The propensity score for receiving each BAS was
erived using multiple logistic regression models. Variables
sed to derive these propensity scores included demographics
age, sex, race/ethnicity), clinical characteristics (body mass
ndex, NYHA heart failure classification), coronary artery
All CathPCI Paents 7/
606,382
Final Study Pop
570,777
Men 
385,103 (67.5%)
Figure 1 Study Population
A total of 606,382 patients were in the CathPCI Registry from July 1, 2009 to Ma
570,777 patients at 1,230 sites remained. Among the final study cohort, 385,10isease risk factors (diabetes, hypertension, dyslipidemia, gmoking, family history of coronary artery disease), coronary
rtery disease history (previous PCI, coronary artery bypass
raft surgery, myocardial infarction), other cardiovascular dis-
ase history (congestive heart failure, cerebrovascular disease,
eripheral vascular disease), other disease history (chronic
bstructive pulmonary disease, renal failure), and presenting
yndrome (no symptoms, atypical chest pain, stable angina,
nstable angina, STEMI, and NSTEMI) (11). Given the
maller numbers of patients within certain BAS groups (e.g.,
ivalirudin plus radial) and potential loss of a significant
ortion of the population with propensity matching, inverse
robability-weighted estimators were used (18). Compared
ith matching and stratification, semiparametric inverse
robability-weighted estimators require few distributional as-
umptions about underlying data, and they avoid the potential
esidual confounding that arises from stratification on a fixed
umber of strata (19). Finally, the absolute differences in
leeding risk for each BAS compared with none were deter-
ined for women and men using chi-square tests.
All statistical analyses were performed using Statistical Analytic
ystems version 9.2 (SAS Institute, Cary, North Carolina). The
tudy was approved by the Institutional Review Board of Duke
niversity Medical Center and was determined to meet the
efinition of research not requiring informed consent.
esults
tudy population characteristics. Baseline demographic
nd clinical characteristics for women and men are shown in
able 1. Compared with men, women were older and more
ikely to have higher NYHA class, have a lower estimated
9-3/31/11
n
Women 
185,674 (32.5%)
35,605 (5.9%) Excluded:
-1,997 Not Femoral or Radial access
-12,488 >1 Percutaneous coronary intervenon
-12,746 Cardiogenic shock
-568 Died the day of procedure 
-165 Missing data to determine bleeding
-7,382 Manual compression and closure device
-106 Radial access and closure device
-153 Radial access, closure device and bilvalirudin
, 2011. After applying exclusions (total of 5.9% excluded),
5%) were men and 185,674 (32.5%) were women.01/0
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May 21, 2013:2070–8 Sex and Bleeding Avoidance Strategiessurface area. Admissions symptoms, procedural details, and
hospital characteristics for women and men are shown in
Table 2. Women more often presented with an acute
coronary syndrome (NSTEMI or unstable angina) com-
pared with men and less often underwent PCI for an
emergency procedure or for an emergent indication.
According to the CathPCI Registry bleeding risk model
V4, the mean  SD estimated bleeding risk was signifi-
antly higher for women than for men (8.0  7.1% vs. 4.0 
.9%; p 0.01). Women were significantly more likely to be
Demographic and Clinical Characteristics by SeTable 1 Demographic and Clinical Characte
Characteristics Men (N 
Demographics
Age, yrs 63.3
White 8
Clinical characteristics
Body mass index, kg/m2 29.8
Body surface area 2.1
New York Heart Association class
I 1
II 3
III 3
IV 1
Coronary artery disease risk factors
Diabetes 3
Hypertension 7
Dyslipidemia 7
Current/recent smoker 2
Family history of coronary disease 2
Coronary artery disease history
Previous PCI 3
Previous CABG 1
Previous myocardial infarction 2
Other cardiovascular disease history
Congestive heart failure
Cerebrovascular disease 1
Peripheral vascular disease 1
Previous valve surgery
Other disease history
Chronic lung disease 1
Previous renal failure
Test information
Estimated glomerular filtration rate 78.7
Left ventricular ejection fraction 51.2
Pre-procedural hemoglobin, g/dl 14.1
Estimated pre-procedural bleeding risk*
Bleeding risk, % 4.0
Categories of risk
High (5%) 2
Intermediate (2.3%–5.0%) 3
Low (2.3%) 4
Values are mean  SD or %. *Based on National Cardiovascular Data
mass index, previous cerebrovascular disease, chronic lung disease, pr
diabetes mellitus, left ventricular ejection fraction, chronic kidney
infarction, non–ST-segment elevationmyocardial infarction, cardiac arr
glomerular filtration rate, pre-procedure hemoglobin, pre-procedure Th
lytics before PCI, subacute stent thrombosis, Society for Cardiovascul
CABG  coronary artery bypass graft.ategorized as either at high (54.1% vs. 23.3%) or interme- adiate (38.9% vs. 30.7%) risk for bleeding compared with
men; only 7% of women compared with 46% of men were
categorized as low risk for predicted bleeding (p  0.01 for
all) (Table 1).
Bleeding outcomes by sex. Following PCI, 7.8% of
women and 3.7% of men experienced a bleeding event (p 
.01). The rates of all of the components of the composite
leeding outcome were significantly higher among women
ompared with men, with the exception of lower rates of
enitourinary bleeding (0.05% vs. 0.07%, p  0.01). Both
s by Sex
,103) Women (N  185,674) p Value
8 67.1 12.3 0.01
86.0 0.01
30.4 7.4 0.01
1.8 0.2 0.01
0.01
10.6
29.3
36.5
23.1
39.8 0.01
85.0 0.01
78.9 0.04
25.9 0.01
25.5 0.01
31.1 0.01
13.6 0.01
23.6 0.01
12.7 0.01
16.1 0.01
13.0 0.01
1.4 0.80
17.6 0.01
2.6 0.01
2 70.8 30.1 0.01
1 54.8 12.1 0.01
12.7 1.7 0.01
8.0 7.l 0.01
0.01
54.1
38.9
7.0
CI Registry Bleeding risk model v4, which accounts for age, sex, body
ercutaneous coronary intervention (PCI), peripheral vascular disease,
, cardiogenic shock, PCI status, ST-segment elevation myocardial
in 24 h, pre-procedure New York Heart Association Class IV, estimated
lysis In Myocardial Infarction flow, number of diseased vessels, use of
ography and Intervention lesion class, and lesion location.xristic
385
 11.
9.5
 5.9
 0.2
3.5
1.6
4.9
9.4
2.4
8.9
9.2
8.5
4.3
4.9
9.1
7.8
9.5
0.2
1.1
1.4
2.9
1.9
 30.
 12.
 1.8
 3.9
3.3
0.7
6.0
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Sex and Bleeding Avoidance Strategies May 21, 2013:2070–8frequent in women. The largest contributors to bleeding events
for both sexes were related to post-PCI transfusions and
hemoglobin decreases 3 g/dl (Online Table 2). In the
leeding outcomes models adjusted for patient, procedural
Admission and Hospital Characteristics by SexTable 2 Admission and Hospital Characteris
Characteristics
Admission presentation
Symptoms
No symptoms
Atypical chest pain
Stable angina
Unstable angina
Non–ST-segment elevation myocardial infarction
ST-segment elevation myocardial infarction
Cardiac arrest within 24 h
Procedure status
Elective
Urgent
Emergency
Salvage
No. vessels intervened upon
1
2
3
Lesion characteristics
Pre-procedure TIMI flow
Complete
Partial
Slow
No
Subacute stent thrombosis
SCAI lesion class
I
II
III
IV
Lesion location
Proximal left anterior descending
Left main
Other
Hospital characteristics
Region
West
Northeast
Midwest
South
Community type
Rural
Urban
Profit type
Government
Private/community
University
Annual PCI volume
Values are % or mean  SD.
SCAI Society for Cardiovascular Angiography and Intervention; TIMharacteristics, site characteristics, and the inverse probability- aeighted estimators to receive BAS, women were more than
wice as likely to bleed compared with men (odds ratio [OR]:
.23, 95% confidence interval [CI]: 2.17 to 2.30).
se of BAS by sex and bleeding risk. Overall, the use of
by Sex
Men
 385,103)
Women
(N  185,674) p Value
0.01
9.6 8.0
3.0 3.5
18.5 18.3
34.7 37.8
17.8 19.1
16.4 13.2
1.17 0.85 0.01
0.01
44.7 44.3
37.4 41.1
17.8 14.5
0.1 0.1
0.01
85.8 86.8
13.1 12.2
0.8 0.8
0.01
53.9 59.5
19.3 19.4
9.3 8.9
17.2 13.0
0.09 0.07 0.03
0.01
44.3 49.3
37.8 37.3
4.8 3.9
13.0 9.4
0.01
15.0 15.2
1.5 1.5
82.9 82.9
0.01
15.4 13.7
15.2 14.4
29.2 30.0
40.3 41.9
0.01
10.5 10.8
89.5 89.2
0.01
1.9 1.7
85.8 86.9
12.3 11.5
8.3 613.7 904.6 622.0 0.02
rombolysis in Myocardial Infarction; other abbreviations as in Table 1.tics
(N
89ny BAS was statistically different in women and in men,
0
r
u
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May 21, 2013:2070–8 Sex and Bleeding Avoidance Strategiesbut absolute differences were small (overall use of BAS in
women 75.4% vs. men 75.7%, p  0.01; absolute difference
.3%). Compared with men, women were more likely to
eceive bivalirudin (31.0% vs. 27.5%, p 0.01), less likely to
ndergo a radial approach (3.0% vs. 3.5%, p  0.05), or
have a closure device deployed (16.4% vs. 18.6%, p  0.01).
BAS of any type was used the least often in both women
and in men at highest risk for bleeding compared with those
in the lower-risk tertiles (men: 63.9% high vs. 76.4%
intermediate and 81.2% low; women: 71.4% high vs. 79.7%
intermediate and 82.4% low; p  0.01 for both). Further,
the interaction of sex and risk category for receiving BAS
was statistically significant (p  0.01), suggesting that the
use of BAS significantly varied by sex and risk category, with
the largest sex differences in BAS use seen among the
highest risk women and men (71.4% vs. 63.9%).
BAS and bleeding risk by sex. Women who did not
receive BAS had significantly more bleeding events follow-
ing PCI compared with men who did not receive BAS
(crude rates of 12.6% vs. 6.2%, p  0.01). For women and
men, the use of all BAS types was associated with a similarly
lower relative risk of bleeding compared with no BAS. In
the multivariable models adjusting for patient characteris-
tics, procedural information, hospital data, clustering by
site, and the propensity to receive each BAS, both women
and men had significantly lower odds of bleeding with each
BAS strategy compared with no BAS (Fig. 2). There was no
significant interaction between sex and specific BAS type
with the exception of the radial approach plus bivalirudin
0.1
No BAS
VCD
Bival Only
Bival + VCD
Radial Only
Radial + Bival
Decrease r
Gender
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Any BAS MenWomen
Bleeding
Avoidance
Strategy OR, 95% CI(men vs women)
0.62 (0.57-0.63)
0.64 (0.61-0.69)
0.67 (0.63-0.71)
0.74 (0.70-0.78)
0.71 (0.67-0.74)
0.42 (0.39-0.45)
0.41 (0.39-0.45)
0.50 (0.44-0.58)
0.48 (0.41-0.56)
0.46 (0.36-0.58)
0.31 (0.23-0.40)
1.0
1.0
Men
Women
0.60 (0.57-0.63)
Figure 2 Relative Differences in Peri-Procedural Bleeding Risk
In the multivariable models adjusting for patient characteristics, procedural inform
avoidance strategy (BAS), both women and men had significantly lower odds of ble
tion between sex and specific BAS type with the exception of the radial approach
in women than in men (p  0.02 for interaction). CI  confidence interval; OR  ogroup, where the relative risk ratio was significantly greater
in women than in men (p  0.02 for interaction) (Fig. 2).
Given the higher bleeding risk for women among all
BAS strata, the absolute differences in bleeding associ-
ated with each BAS compared with none were greater in
women (range: 4.1% to 9.5%) than in men (range: 2.2% to
4.4%) (Fig. 3). Compared with the bleeding risk associated
with the use of no BAS, the largest absolute differences in
bleeding risk were seen among women and men who
underwent the radial approach and received bivalirudin
(9.5% absolute bleeding risk difference in women; 4.4%
absolute bleeding risk difference in men) (Fig. 3).
Discussion
In this contemporary cohort of over 500,000 patients who
underwent PCI at over 1,200 hospitals throughout the
United States, women had twice the risk of bleeding
compared with men. Although a risk treatment paradox was
seen for both women and men, with those at highest risk for
bleeding being the least likely to receive BAS, women and
men were overall similarly likely to receive any form of BAS
following PCI. Finally, all BAS were associated with similar
differences in bleeding risk regardless of sex; however, given
the higher bleeding risk in women, the absolute differences
in bleeding risk associated with all BAS were almost two
times higher in women compared with men.
Although others have reported sex differences in bleeding
following PCI, our study expands the literature in several
ways (4–10). First, our study reflects a contemporary com-
0.5 2.5
Increase risk of Bleeding 
P values for Interaction
leeding 
0.02
0.32 
0.24
0.83
0.50
1.0
0.45 
S and Sex
hospital data, clustering by site, and the propensity to receive each bleeding
with each BAS strategy compared with no BAS. There was no significant interac-
ivalirudin (bival) group, where the relative risk difference was significantly greater
atio; VCD  vascular closure device.isk of B
by BA
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Sex and Bleeding Avoidance Strategies May 21, 2013:2070–8parison of peri-procedural bleeding in women and in men
from 2009 to 2011, a time in which advances in pharma-
cological agents (i.e., the use of bivalirudin) and procedural
techniques (i.e., increased use of a radial approach) occurred
(13,20,21). Second, our study includes the largest cohort of
women and men who underwent PCI throughout the
United States. Finally, our study employs an established and
broad definition for peri-procedural bleeding. The CathPCI
Registry definition of bleeding includes not only bleeding at
the access site, but also bleeding at nonaccess sites, and
post-procedural transfusion or an absolute decrease in he-
moglobin (22). This definition is similar to the bleeding
definitions used in contemporary clinical trials of PCI
procedures that focus on both access- and nonaccess-related
bleeding as a primary outcome (23). Bleeding of various
degrees, including minor bleeding, among patients under-
going PCI is associated with increased risk of mortality and
morbidity, longer hospital stay, and increased costs; there-
fore, a heterogeneous definition for bleeding allows a greater
sensitivity to detect patients at higher risk for poor outcomes
(1,24,25).
The present study demonstrates that in contemporary
practice women have almost twice the rate of bleeding
compared with men following PCI (7.8% vs. 3.7%, adjusted
OR: 2.23, 95% CI: 2.17 to 2.30), despite the relatively
Any BAS VCD only
14
12
10
8
6
4
2
0
No BAS
 Treatment No (%)
 Men 93,553 (24.3) 291,550 (75.7) 71,736 (18.6) 
 Women 45,679 (24.6) 139,995 (75.4) 30,357 (16.3) 
 Absolute Reduction in Bleeding
 Men – 3.2% 2.2% 
 Women – 6.4% 4.1% 
*
*
*
%
 B
le
ed
in
g 
ev
e
n
t
Figure 3 Peri-Procedural Bleeding Rates and Absolute Differenc
Women who did not receive BAS had significantly more bleeding events following p
12.6% vs. 6.2%, p  0.01). Given the higher bleeding risk for women among all B
with none were greater in women (range: 4.1% to 9.5%) than in men (range: 2.2%frequent use of BAS. Over the last 2 decades, numerousstudies have similarly demonstrated significantly higher
rates of post-procedural bleeding in women (4–10,26).
Another important contribution of this study is that we
found that approximately 3 of 4 women and men undergo-
ing PCI receive any type of BAS. Although overall BAS use
was similar in women and in men, our study confirms the
presence of a risk treatment paradox for both women and
men (11). Future studies are needed to investigate potential
reasons for lower rates of BAS use among the highest-risk
patients (11).
One of the most important findings of our study is a
comparison of the relative and absolute risk differences in
bleeding associated with different types of BAS among
women and men. Overall, each BAS strategy studied was
associated with similarly lower relative risks of bleeding in
women and men compared with the use of no BAS.
Although several studies have demonstrated reductions in
bleeding risk with BAS compared with none, few have
evaluated these relationships by sex (4,9). Our study sug-
gests a slightly greater benefit of the combined use of the
transradial approach and bivalirudin in women compared
with men (reduction in bleeding: 69% in women vs. 54% in
men, p  0.02 for interaction). However, these findings
should be interpreted with caution because the numbers of
women and men undergoing a radial approach and receiving
Bival only Bival + VCD Radial only Radial + Bival
05,811 (27.5) 92,151 (23.9) 13,342 (3.5) 8,510 (2.2)
57,632 (31.3) 42,618 (23.0)   5,557 (3.0) 3,831 (2.1)
2.9% 4.2% 4.1% 4.4%
5.8% 8.3% 8.0% 9.5%
*
* *
*
Men
Women
* P<0.01 for all
Bleeding Risk by BAS and Sex
neous intervention compared with men who did not receive BAS (crude rates of
ata, the absolute differences in bleeding associated with each BAS compared
%). Abbreviations as in Figures 1 and 2.1
  
es in
ercuta
AS str
to 4.4bivalirudin was relatively small. Additional studies are
2077JACC Vol. 61, No. 20, 2013 Daugherty et al.
May 21, 2013:2070–8 Sex and Bleeding Avoidance Strategiesneeded to confirm whether 1 type of BAS will prove to be
more effective in women than in men.
Although we found similarly lower relative risk differ-
ences associated with all BAS types, the absolute differences
in bleeding risk for women were approximately 2-fold
higher than in men because of the higher baseline predicted
risk of bleeding in women. For example, women who
received bivalirudin and a VCD had an 8.3% absolute
difference in bleeding risk compared with a 4.2% absolute
difference among men. Absolute differences of this magni-
tude would result in an estimated number needed to treat to
prevent 1 bleed of 12 for women and 24 for men. Given
their significantly higher risk of bleeding, use of BAS in
women might prevent a greater proportion of bleeding
events; therefore, a low clinical threshold for BAS use
among women should be considered.
Study limitations. First, controversy exists as to whether
the BAS types examined in this study are efficacious in
reducing bleeding. Specifically, studies on the safety of
VCDs have shown increased, decreased, or neutral bleeding
complications (13). Further, the extent to which bivalirudin
reduces bleeding compared with unfractionated heparin
alone is not well known (13). The present study suggests
that the BAS types examined are associated with similar
relative differences in bleeding in women and in men
following PCI; however, randomized trials are needed to
define the most efficacious strategy for bleeding avoidance.
Second, bleeding outcomes are based on site documentation
and may be underestimated. However, we used a definition
for bleeding that included documentation of a bleeding
event and objective drops in hemoglobin, which were the
largest portion of bleeding events for women and men.
Further, the definition was applied equally to women and
men, and documentation would not be expected to vary by
sex. Third, the CathPCI Registry only captures in-hospital
bleeding events and does not evaluate longitudinal outcomes
following discharge. However, in multiple studies, in-
hospital bleeding events have been associated with longer-
term morbidity and mortality (1–3). Fourth, the present
analysis does not account for sheath size, which has been
shown to be associated with differences in post-procedural
bleeding among women compared with men (4,9). How-
ever, sheath size has been associated with adverse bleeding
at the access site, and many of our bleeding outcomes were
not access specific. Fifth, we were unable to account for
possible sex differences in the dosing of either antithrom-
botic or antiplatelet agents. Previous studies have demon-
strated that women were more likely to receive inappropri-
ately high doses of both antithrombotic and antiplatelet
agents, which may partially explain higher rates of bleeding
in women (27). It is not clear, however, that rates of
inappropriate dosing would necessarily differ among strata
of BAS use. Finally, given the observational nature of our
data, the possibility of residual unmeasured confounding
may explain the differences in risk associated with BAS in
our study. We attempted to minimize confounding bycalculating a non-parsimonious propensity score for receiv-
ing each type of BAS among women and men and using
inverse probability-weighted estimators.
This study has several implications for clinical care and
future research. First, we demonstrated that sex differences
in bleeding following PCI are not largely due to differences
in BAS use. Second, although the risk treatment paradox for
BAS use is present for women and men, it did not differ
markedly between them. Third, the relative risk difference
associated with each BAS was similar between women and
men, with the exception of slightly greater differences in
bleeding risk with the combined use of the radial approach
and bivalirudin in women. Taken together, these findings
suggest that persistent sex differences in bleeding post-PCI
are not due to differences in the apparent effectiveness of
BAS. Finally, the absolute reductions in bleeding risk were
almost 2 times higher in women compared with men for all
BAS types. Therefore, our findings underscore the impor-
tance of comparing available strategies and developing new
approaches to reduce bleeding risk in women following PCI.
One such trial is currently ongoing (SAFE-PCI for Women;
NCT01406236).
Conclusions
In contemporary practice, women have almost twice the risk
of bleeding following PCI. The use of BAS was associated
with significantly lower bleeding risks for both men and
women; however, the absolute risk differences were higher
in women. These data underscore the importance of apply-
ing effective strategies to limit post-PCI bleeding, especially
in women.
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